<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820530</url>
  </required_header>
  <id_info>
    <org_study_id>CLNP023C12301</org_study_id>
    <secondary_id>2020-003172-41</secondary_id>
    <nct_id>NCT04820530</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy</brief_title>
  <acronym>APPOINT-PNH</acronym>
  <official_title>A Multicenter, Single-arm, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily Iptacopan in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 3 study is to determine whether iptacopan is efficacious and safe&#xD;
      for the treatment of PNH patients who are naive to complement inhibitor therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this single arm, open label study is to determine whether iptacopan is&#xD;
      efficacious and safe for the treatment of PNH patients who are naive to complement inhibitor&#xD;
      therapy, including anti-C5 antibody.&#xD;
&#xD;
      The study is planned to have approximately 40 PNH patients starting study treatment in&#xD;
      various countries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">July 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 23, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants achieving a sustained increase in hemoglobin levels of ≥ 2 g/dL in the absence of red blood cell transfusion</measure>
    <time_frame>Day 168</time_frame>
    <description>Proportion of participants achieving a sustained increase from baseline in hemoglobin levels of ≥ 2 g/dL assessed , in the absence of red blood cell transfusions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving sustained hemoglobin levels ≥ 12 g/dL in the absence of red blood cell transfusions</measure>
    <time_frame>Day 168</time_frame>
    <description>Proportion of participants achieving sustained hemoglobin levels ≥ 12 g/dL in absence of red blood cell transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion avoidance (TA) defined as the proportion of participants who remain free from transfusions</measure>
    <time_frame>Day 14 and Day 168</time_frame>
    <description>Transfusion avoidance (TA) defined as the proportion of participants who remain free from transfusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemoglobin</measure>
    <time_frame>Day 126 and Day 168</time_frame>
    <description>Change from baseline in hemoglobin (g/dL) as mean of visits between Day 126 and Day 168</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in LDH</measure>
    <time_frame>Day 126 and Day 168</time_frame>
    <description>Percent change from baseline in LDH levels (U/L) as mean of visits between Day 126 and Day 168</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of breakthrough hemolysis (BTH)</measure>
    <time_frame>Day 1 and Day 168</time_frame>
    <description>Occurrences of breakthrough hemolysis reported between Day 1 and Day 168</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in reticulocyte counts</measure>
    <time_frame>Day 126 and Day 168</time_frame>
    <description>Change from baseline in reticulocyte counts as mean of visits between Day 126 and Day 168</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fatigue score, using the FACIT-Fatigue questionnaire</measure>
    <time_frame>Day 126 and Day 168</time_frame>
    <description>Change from baseline in FACIT-Fatigue scores as mean of visits between Day 126 and Day 168</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Major Adverse Vascular Events (MAVEs incl. thrombosis)</measure>
    <time_frame>Day 1 and Day 168</time_frame>
    <description>Occurrences of MAVEs occurring between Day 1 and Day 168</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria (PNH)</condition>
  <arm_group>
    <arm_group_label>LNP023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive LNP023 at a dose of 200 mg orally b.i.d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iptacopan (LNP023)</intervention_name>
    <description>Taken orally b.i.d. Dosage supplied: 200mg Dosage form: Hard gelatin capsule Route of Administration: oral</description>
    <arm_group_label>LNP023</arm_group_label>
    <other_name>Iptacopan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female participants ≥ 18 years of age with a diagnosis of PNH confirmed by&#xD;
             high-sensitivity flow cytometry with clone size ≥ 10%&#xD;
&#xD;
          -  Mean hemoglobin level &lt;10 g/dL&#xD;
&#xD;
          -  LDH &gt; 1.5 x Upper Limit of Normal (ULN)&#xD;
&#xD;
          -  Vaccination against Neisseria meningitidis infection is required prior to the start of&#xD;
             study treatment&#xD;
&#xD;
          -  If not received previously, vaccination against Streptococcus pneumoniae and&#xD;
             Haemophilus influenzae infections should be given&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with a complement inhibitor, including anti-C5 antibody&#xD;
&#xD;
          -  Known or suspected hereditary complement deficiency&#xD;
&#xD;
          -  History of hematopoietic stem cell transplantation&#xD;
&#xD;
          -  Patients with laboratory evidence of bone marrow failure (reticulocytes &lt;100x109/L;&#xD;
             platelets &lt;30x109/L; neutrophils &lt;0.5x109/L).&#xD;
&#xD;
          -  Active systemic bacterial, viral (incl. COVID-19)or fungal infection within 14 days&#xD;
             prior to study drug administration.&#xD;
&#xD;
          -  History of recurrent invasive infections caused by encapsulated organisms, e.g.&#xD;
             meningococcus or pneumococcus.&#xD;
&#xD;
          -  Major concurrent comorbidities including but not limited to severe kidney disease&#xD;
             (e.g., dialysis), advanced cardiac disease (e.g., NYHA class IV heart failure), severe&#xD;
             pulmonary disease (e.g., severe pulmonary hypertension (WHO class IV)), or hepatic&#xD;
             disease (e.g., active hepatitis) that in the opinion of the investigator precludes&#xD;
             participant's participation in the study.&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Avellino</city>
        <state>AV</state>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suita city</city>
        <state>Osaka</state>
        <zip>565 0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa ku</city>
        <state>Tokyo</state>
        <zip>141 8625</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paroxysmal nocturnal hemoglobinuria</keyword>
  <keyword>Hemoglobin</keyword>
  <keyword>Anemia</keyword>
  <keyword>LNP023</keyword>
  <keyword>Iptacopan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient level data and supporting clinical documents from eligible studies. these requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

